However, diltiazem acts
Diltiazem (DTZ) is a calcium channel blocker widely used in the treatment
The metabolism of DTZ in the liver generated large amounts of MA but no M1, and in the small intestine, modest amounts of both metabolites
More than 90% of oral diltiazem is absorbed, with approximately 45% bioavailability (first-pass hepatic metabolism)
Deacetyldiltiazem (M1) and N-demethyldiltiazem (MA) are 2 of the main basic
To study whether intravenous diltiazem, a calcium channel blocker commonly prescribed for hypertension and stable angina, is an inhibitor of the CYP3A enzymes by using oral
After serial blood sampling, the rabbits were sacrificed, and diltiazem, MA and M1 constant rates of metabolism (Kmet) were estimated in the 10,000 x g supernatants of the intestinal mucosa, liver Diltiazem causes vasoconstriction in the liver when present at high concentrations, an action that is strictly Ca2+-dependent
Patients currently receiving diltiazem therapy should be carefully monitored for a change in pharmacological effect when initiating and discontinuing therapy with cimetidine
UN-induced ARF (UN-ARF) increased the in vitro hepatic clearance (CLvit) of DTZ 1
We observed the anticipated decreases in total clearance of diltiazem
Diltiazem undergoes extensive hepatic metabolism in which 2% to 4% of the unchanged drug appears in the urine
Metabolism is hepatic, and excretion is mainly biliary
Thus, both verapamil and diltiazem causes significant bradycardia, hypotension, conduction disturbances, and escape rhythms
Despite long usage of some of these drugs (e
Diltiazem and verapamil competitively inhibited the N-demethylation of aminopyrine in hepatic microsomes with Ki values of 100 and 140 microM respectively
Diltiazem causes vasoconstriction in the liver when present at high concentrations, an action that is strictly Ca2+-dependent
Diltiazem causes vasoconstriction in the liver when present at high concentrations, an action that is strictly Ca2+-dependent
Patients currently receiving diltiazem therapy should be carefully monitored for a change in pharmacological effect when initiating and discontinuing therapy with cimetidine
The effect may be mediated by cimetidine’s known inhibition of hepatic cytochrome P-450, the enzyme system responsible for the first-pass metabolism of diltiazem
Diltiazem causes vasoconstriction in the liver when present at high concentrations, an action that is strictly Ca2+-dependent